aquapharm_bertrand_lehuu

Bertrand Lehuu joins Aquapharm

pharmafile | March 24, 2011 | Appointment | Research and Development appointment, research and development 

Scottish marine biotechnology company Aquapharm Biodiscovery has appointed Bertrand Lehuu as senior VP – pharma business.

Bertrand has almost 30 years’ experience in senior pharma and biotech roles and will at Aquapharm he will be responsible for bio-pharmaceutical business development.

His career to date has encompassed stints at the Pasteur Institute, Flamel Technologies, F-Hoffmann La Roche, Basilea, Neuro3d, BioXell and, most recently, PharmaSwiss.

Advertisement

At Aquapharm Bertrand will play a strategic role in the development and future growth of the company which, in the last year alone, has attracted a significant amount of funding and struck several research partnerships.

He said: “Aquapharm is a dynamic and talented company and I am excited to be in this new role working with one of the UK’s most promising biotech firms. Right now it is breaking new ground with its pioneering research into marine natural products.

“I am delighted to be joining its high calibre team on what promises to be one of the most innovative sources of new chemistry for the pharma industry.”

In the last year Aquapharm has reshuffled its senior management team, appointing Mats Pettersson to the board, Prof Simon Best as chief executive, Dr Tim Morley as chief scientific officer and moving Aquapharm founder Dr Andrew Mearns Spragg to the role of chief technology officer.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content